JP7663502B2 - 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療 - Google Patents

環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療 Download PDF

Info

Publication number
JP7663502B2
JP7663502B2 JP2021548548A JP2021548548A JP7663502B2 JP 7663502 B2 JP7663502 B2 JP 7663502B2 JP 2021548548 A JP2021548548 A JP 2021548548A JP 2021548548 A JP2021548548 A JP 2021548548A JP 7663502 B2 JP7663502 B2 JP 7663502B2
Authority
JP
Japan
Prior art keywords
subject
seq
pharmaceutical composition
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021548548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509525A5 (https=
JP2022509525A (ja
Inventor
ラアデム アブデラーマン
チャン シアンジュアン
エム．アティエ ケネス
ジー． リンデ ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2022509525A publication Critical patent/JP2022509525A/ja
Publication of JP2022509525A5 publication Critical patent/JP2022509525A5/ja
Application granted granted Critical
Publication of JP7663502B2 publication Critical patent/JP7663502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021548548A 2018-10-31 2019-10-30 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療 Active JP7663502B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753379P 2018-10-31 2018-10-31
US62/753,379 2018-10-31
PCT/US2019/058803 WO2020092523A1 (en) 2018-10-31 2019-10-30 TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS

Publications (3)

Publication Number Publication Date
JP2022509525A JP2022509525A (ja) 2022-01-20
JP2022509525A5 JP2022509525A5 (https=) 2022-11-07
JP7663502B2 true JP7663502B2 (ja) 2025-04-16

Family

ID=70464629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548548A Active JP7663502B2 (ja) 2018-10-31 2019-10-30 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療

Country Status (6)

Country Link
US (1) US20210346464A1 (https=)
EP (1) EP3873501A4 (https=)
JP (1) JP7663502B2 (https=)
KR (1) KR20210088548A (https=)
CN (1) CN112969471A (https=)
WO (1) WO2020092523A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537921A (ja) 2014-12-03 2017-12-21 アクセルロン ファーマ， インコーポレイテッド 骨髄異形成症候群および鉄芽球性貧血を処置するための方法
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
JP2018520094A (ja) 2015-05-13 2018-07-26 セルジーン コーポレイション ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3638243T3 (pl) * 2017-06-14 2025-02-10 Celgene Corporation Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537921A (ja) 2014-12-03 2017-12-21 アクセルロン ファーマ， インコーポレイテッド 骨髄異形成症候群および鉄芽球性貧血を処置するための方法
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
JP2018520094A (ja) 2015-05-13 2018-07-26 セルジーン コーポレイション ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lancet Oncol.，2017年09月，Vol. 18, no. 10，p. 1338-1347

Also Published As

Publication number Publication date
EP3873501A4 (en) 2022-07-13
US20210346464A1 (en) 2021-11-11
EP3873501A1 (en) 2021-09-08
CN112969471A (zh) 2021-06-15
JP2022509525A (ja) 2022-01-20
KR20210088548A (ko) 2021-07-14
WO2020092523A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7663502B2 (ja) 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療
Berek et al. Biologic and immunologic therapies for ovarian cancer
Wei et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine
US9149504B2 (en) Compositions and methods for treatment of neoplastic disease
Chari et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study
EP2400021B1 (en) ErbB3 based methods and compositions for treating neoplasms
EA023344B1 (ru) Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией
CN110167594A (zh) 皮下her2抗体配制剂
Berglund et al. First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
JP2018537536A (ja) Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法
Neidhart et al. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.
Estey Prognosis and therapy of secondary myelodysplastic syndromes
Wei et al. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes
Thaker et al. OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
Santini et al. Treatment of myelodysplastic syndrome with thrombomimetic drugs
WO2003068155A2 (en) Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
CN112584861A (zh) 使用组合疗法治疗癌症的方法
Tano et al. Novel immunotherapy clinical trials in malignant pleural mesothelioma
EP4711444A2 (en) Endothelial cells for mitigation of chemotherapy-induced toxicity
CN115120744A (zh) 重组人内皮抑素腺病毒与抗pd-1抗体或抗pd-l1抗体在制备抗肿瘤药物中的用途
CN102935228B (zh) 用于肿瘤治疗的试剂、其用途及方法
JP2024526975A (ja) Ｈｅｒ２ワクチン組成物
Meyer et al. Treatment of a locally invasive cutaneous Fusarium species infection with voriconazole and liposomal Amphotericin B in a patient with relapsed acute myeloid leukemia
IL300528A (en) Immune conjugates targeting cd46 and methods of using them
Czyżykowski et al. Granulocyte colony-stimulating factor in supportive treatment in oncology and hematology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250404

R150 Certificate of patent or registration of utility model

Ref document number: 7663502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150